AKBA — Akebia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517022 ·
Last close
$1.04
Market Cap
$278.99M
52W High
$1.60
52W Low
$0.88
ADV30
4,482,279
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 53,544,000 | 41,254,000 | -4,696,000 | -9,054,000 | 362,520,000 | 162,644,000 | 335,145,000 |
| Dec 2025 | 57,622,000 | 45,087,000 | -8,553,000 | -12,244,000 | 376,565,000 | 184,844,000 | 343,955,000 |
| Sep 2025 | 58,766,000 | 49,383,000 | 4,449,000 | 540,000 | 364,152,000 | 166,444,000 | 322,560,000 |
| Jun 2025 | 62,472,000 | 52,553,000 | 14,089,000 | 247,000 | 345,595,000 | 137,308,000 | 316,371,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$67,992,000
Investing CF
$-7,926,000
Financing CF
$72,927,000
CapEx
$-8,098,000
Dividends Paid
—
Buybacks
$-63,000
EPS Diluted TTM
$-0.02
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,683,705,000
Inventory
$15,610,000
Receivables
$47,031,000
ST Investments
—
EBIT TTM
$20,458,000
Pretax Income TTM
$-3,721,000
Interest Exp TTM
$24,179,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$232,404,000
EBITDA
$12,130,000
Free Cash Flow
$65,809,876
Enterprise Value
$308,503,392
Total Cash
$162,644,000
Total Debt
$197,524,000
Shares Out
268,258,243
Trailing EPS
$-0.08
Book Value
$0.10
ROE
-79.0%
ROA
2.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 236,196,000 | 23,499,000 | -5,345,000 | 376,565,000 | 343,955,000 | — | 67,992,000 |
| Dec 2024 | 160,180,000 | -50,414,000 | -69,410,000 | 220,670,000 | 269,855,000 | — | -40,659,000 |
| Dec 2023 | 194,623,000 | -46,075,000 | -51,925,000 | 241,703,000 | 272,287,000 | — | -23,384,000 |
| Dec 2022 | 292,484,000 | -64,846,000 | -94,226,000 | 356,054,000 | 350,824,000 | — | -73,154,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$37,428,000
NetIncome TTM
$-20,039,000
OpCashFlow TTM
$0
Assets (Latest)
$220,670,000
Forward EPS
$-0.19
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZNTL | Zentalis Pharmaceuticals, Inc. | $281.90M | $3.96 | — |
| MGNX | MACROGENICS INC | $284.13M | $4.47 | — |
| NVCT | Nuvectis Pharma, Inc. | $267.91M | $10.10 | — |
| PRLD | Prelude Therapeutics Inc | $265.51M | $4.09 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $264.43M | $1.73 | — |
News headlines (Yahoo Finance, 1h cache)
Promising Penny Stocks To Consider In May 2026
2026-05-26 12:05 · Yahoo
Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results
2026-05-11 12:27 · Yahoo
Akebia (AKBA) Q1 2026 Earnings Transcript
2026-05-08 15:12 · Yahoo
Akebia Therapeutics Q1 Earnings Call Highlights
2026-05-07 13:22 · Yahoo
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights
2026-05-07 11:00 · Yahoo
United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates
2026-05-06 11:45 · Yahoo
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-04 20:05 · Yahoo
Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal
2026-05-04 12:00 · Yahoo
Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights
2026-04-30 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.